Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Stock data | 2024 | Change |
---|---|---|
Price | $0.365 | N/A |
Market Cap | $21.69M | N/A |
Shares Outstanding | 59.43M | N/A |
Employees | 31.00 | N/A |